ASH/FDA Multiple Myeloma Clinical Endpoints Workshop

Presented by the American Society of Hematology and the U.S. Food and Drug Administration
Co-sponsored by the American Association for Cancer Research and the American Society of Clinical Oncology

Thursday, October 26, 2006
8:30 a.m. – 5:00 p.m.
Palladian Room, Omni Shoreham Hotel, Washington, DC

Advance registration is now open.

Workshop Co-Chairs
Kenneth C. Anderson, MD • Dana-Farber Cancer Institute

Richard Pazdur, MD • Director, Office of Oncology Drug Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

This important workshop on multiple myeloma will explore endpoints that represent clinical benefits other than overall survival in the following areas:

Monoclonal Gammopathy of Unclear Significance (MGUS)
Subcommittee Chair: Robert A. Kyle, MD • Mayo Clinic, Rochester, MN

Newly Diagnosed
Subcommittee Chair: S. Vincent Rajkumar, MD • Mayo Clinic, Rochester, MN

Relapsed
Subcommittee Chair: Donna Weber, MD • M.D. Anderson Cancer Center, Houston, TX

Refractory
Subcommittee Chair: William S. Dalton, MD, PhD • H. Lee Moffitt Cancer Center, The University of South Florida, Tampa, FL

Maintenance
Subcommittee Chair: Jean-Luc Harousseau, MD • University Hospital Hôtel-Dieu, Nantes, France

Registration
There is no registration fee, but attendance is limited. Advance registration is encouraged to ensure an adequate number of seats are available.

Advance online registration is available until October 19, 2006. On site registration will be available if space permits.

Hotel Accommodations
If you need hotel accommodations for the workshop, we recommend that you contact the Omni Shoreham Hotel directly.

Omni Shoreham Hotel
2500 Calvert Street, NW
Washington, DC 20008
Phone: 202-234-0700

Workshop Materials
All workshop materials will be distributed on site on the day of the workshop.

Questions?
Please contact Stephanie Kart, ASH Government Relations and Practice Coordinator, by e-mail or call 202-776-0544.